Publicacións nas que colabora con Jose Miguel Rivera Caravaca (101)

2024

  1. Advances in the medical treatment and diagnosis of intracranial hemorrhage associated with oral anticoagulation

    Expert Review of Neurotherapeutics, Vol. 24, Núm. 9, pp. 913-928

  2. Dynamic assessment of CHA2DS2-VASc and HAS-BLED scores for predicting ischemic stroke and major bleeding in atrial fibrillation patients

    Revista Espanola de Cardiologia, Vol. 77, Núm. 10, pp. 835-842

  3. Impact of prior oral anticoagulation therapies on post-discharge outcomes after COVID-19: Results from a global federated health network analysis

    European Journal of Clinical Investigation

  4. Patients with atrial fibrillation and common exclusion criteria from clinical trials are at high risk of clinical events: the Murcia AF Project II (MAFP-II) cohort study

    Internal and Emergency Medicine, Vol. 19, Núm. 7, pp. 1941-1948

2023

  1. Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Patients With Renal Impairment

    American Journal of Cardiology, Vol. 203, pp. 122-127

  2. Cerebrovascular, Cognitive and Cardiac Benefits of SGLT2 Inhibitors Therapy in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus: Results from a Global Federated Health Network Analysis

    Journal of Clinical Medicine, Vol. 12, Núm. 8

  3. Clinical implications of different types of dementia in patients with atrial fibrillation: Insights from a global federated health network analysis

    Clinical Cardiology, Vol. 46, Núm. 6, pp. 656-662

  4. Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 8-15

  5. High medium-term incidence of major cardiovascular events in discharged patients with unstable angina

    IJC Heart and Vasculature, Vol. 46

  6. Ibrutinib use and adverse cardiovascular outcomes: A United States federated electronic medical records analysis

    European Journal of Internal Medicine

  7. Imaging in atrial fibrillation: A way to assess atrial fibrosis and remodeling to assist decision-making

    American Heart Journal, Vol. 258, pp. 1-16

  8. Impact of particulate matter on the incidence of atrial fibrillation and the risk of adverse clinical outcomes: A review

    Science of the Total Environment, Vol. 880

  9. Impact of renal function on Ticagrelor-induced antiplatelet effects in coronary artery disease patients

    IJC Heart and Vasculature, Vol. 46

  10. Incidence and predictors of sternal surgical wound infection in cardiac surgery: A prospective study

    International Wound Journal, Vol. 20, Núm. 4, pp. 917-924

  11. Molecular mechanisms of postoperative atrial fibrillation in patients with obstructive sleep apnea

    FASEB Journal, Vol. 37, Núm. 6

  12. Peripheral artery disease: Update on etiology, pathophysiology, diagnosis and treatment

    Medicina Clinica, Vol. 161, Núm. 8, pp. 344-350

  13. Polypharmacy and adverse events in atrial fibrillation: Main cause or reflection of multimorbidity?

    Biomedicine and Pharmacotherapy, Vol. 158

  14. Reducing bleeding risk in patients on oral anticoagulation therapy

    Expert Review of Cardiovascular Therapy, Vol. 21, Núm. 12, pp. 923-936

  15. Simplified Geleijnse score for identifying chest pain features associated with coronary ischemia

    Heart and Lung, Vol. 59, pp. 61-66

  16. The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort

    Journal of General Internal Medicine, Vol. 38, Núm. 2, pp. 315-323